10-Methylene-10H-anthracen-9-one | 4159-04-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 蒽
• 英文名称: 10-Methylene-10H-anthracen-9-one
• 英文别名: 9-methyleneanthrone；10-methylene-9-anthrone；10-methylen-anthrone；10-Methylen-anthron；10-Oxo-9-methylen-dihydroanthracen；10-methylene anthrone；Methylenanthron；10-methylideneanthracen-9-one
• CAS: 4159-04-0
• 化学式: C₁₅H₁₀O
• 分子量: 206.244
• InChiKey: SFSLTRCPISPSKB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  16
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  10-Methylene-10H-anthracen-9-one 在 磺酰氯 作用下， 以 二氯甲烷 为溶剂， 反应 3.0h， 以75%的产率得到10-choro-10-(chloromethyl)anthrone
  参考文献：
  名称：

  Preparations and reactions of 10-(halomethylene)anthrones

  摘要：

  DOI：

  10.1021/jo00357a027
• 作为产物：
  描述：

  10-hydroxy-10-methylanthracen-9(10H)-one 在 草酸 、 溶剂黄146 作用下， 反应 0.01h， 生成 10-Methylene-10H-anthracen-9-one
  参考文献：
  名称：

  Aromatic hydroxylation and deacylation of 9-acylanthracenes by copper(II)-peroxydisulfate

  摘要：

  DOI：

  10.1021/jo00223a008

文献信息

• Radical adducts of dibenzofulvenes and 9-methylenanthrone - an esr study
  作者：Angelo Alberti、Gian Franco Pedulli、Rino Leardin、Antonio Tundo、Giuseppe Zanardi

  DOI：10.1016/0040-4020(86)80018-7

  日期：1986.1

  R3M. radicals (M=C, Si, Ge, Sn, P, O, S) to give the corresponding paramagnetic adducts. In the case of 9-methylenanthrone radical addition occurred selectively at the exocyclic carbon-carbon double bond even with Group IV B organometallic radicals for which attack at the carbonyl oxygen would give rise to thermodynamically more stable adducts. When irradiating solutions of 9-methylenanthrone a photoinduced

  使标题化合物与一系列R 3 M.基团（M = C，Si，Ge，Sn，P，O，S）反应，得到相应的顺磁性加合物。在9-亚甲基蒽酮基团的情况下，即使在IV B族有机金属基团上，环碳-碳双键选择性地发生加成，其对羰基氧的攻击将产生热力学上更稳定的加合物。辐射9-甲基蒽酮溶液时，发生了光致自反应，导致形成了二聚体。根据测得的ESR光谱参数，讨论了加合物的结构，以及R n M基团对β-质子超细分裂常数的影响。
• POLYMERIZABLE COMPOUND AND OPTICAL ISOMER
  申请人：DIC Corporation

  公开号：US20180022716A1

  公开（公告）日：2018-01-25

  The present invention provides a polymerizable compound having high storage stability without causing crystal precipitation when added to a polymerizable composition. The present invention also provides a polymerizable composition containing the compound. When the filmy polymer produced through polymerization of the polymerizable composition is irradiated with UV light, it hardly discolors or peels from substrate. Further, the present invention provides a polymer produced through polymerization of the polymerizable composition and an optically anisotropic body using the polymer.

  本发明提供了一种聚合物化合物，具有高储存稳定性，添加到聚合物化合物时不会导致结晶沉淀。本发明还提供了含有该化合物的聚合物化合物。当通过聚合物化合物的聚合产生薄膜状聚合物时，若用紫外光照射，它几乎不会变色或脱落。此外，本发明提供了通过聚合物化合物的聚合产生的聚合物，以及使用该聚合物的光学各向异性体。
• Carbamates and ureas derived from 11-amino-6,11-dihydrodibenzo[b,e]thiepin; Synthesis and pharmacological screening
  作者：Vladimír Valenta、Marie Bartošová、Miroslav Protiva

  DOI：10.1135/cccc19800517

  日期：——

  A series of N-substituted carbamates V-XIII was prepared by reactions of 6,11-dihydrodibenzo[b,e]thiepin-11-ol (I) with carbamates H₂NCOOR in acetic acid. Whereas the Leuckart reaction of dibenzo[b,e]thiepin-11(6H)-one yielded 9-formamido-10-methylene-9,10-dihydroanthracene (XVIII), a satisfactory method for preparing the amine III was found in heating the carbamate V with 2-aminoethanol to 170°C. Reactions of the amine III with isocyanates gave most of the disubstituted ureas XX-XXV. The expected anticonvulsant activity was found only in high doses with compounds IX, XII, XV, XX, XXI and XXXIII.

  一系列N-取代的氨甲酸酯V-XIII通过在乙酸中6,11-二氢二苯并[be]噻吩-11-醇(I)与氨甲酸酯H2NCOOR反应而制备。而二苯并[be]噻吩-11(6H)-酮的Leuckart反应产生了9-甲酰基-10-亚甲基-9,10-二氢蒽(XVIII)，在加热氨甲酸酯V与2-氨基乙醇至170°C的条件下找到了制备胺III的满意方法。胺III与异氰酸酯反应产生了大部分的二取代脲XX-XXV。预期的抗癫痫活性仅在化合物IX、XII、XV、XX、XXI和XXXIII中高剂量下发现。
• Macrocyclic oximyl hepatitis C protease inhibitors
  申请人：Sun Ying

  公开号：US20070281884A1

  公开（公告）日：2007-12-06

  The present invention discloses compounds of formula I, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

  本发明揭示了化合物I的公式，或其药用可接受的盐、酯或前药：这些化合物抑制丝氨酸蛋白酶活性，特别是乙型肝炎病毒（HCV）NS3-NS4A蛋白酶的活性。因此，本发明的化合物干扰了乙型肝炎病毒的生命周期，同时也可用作抗病毒剂。本发明还涉及包含上述化合物的药物组合物，用于治疗患有HCV感染的受试者。该发明还涉及通过给患者投予含有本发明化合物的药物组合物来治疗受试者的HCV感染的方法。
• CARBOCYCLIC OXIME HEPATITIS C VIRUS SERINE PROTEASE INHIBITORS
  申请人：Liu Dong

  公开号：US20090149491A1

  公开（公告）日：2009-06-11

  The present invention discloses compounds of formula I, II, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. More specifically, the invention relates to oxime compounds containing a carbocyclic P2 unit. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

  本发明揭示了化合物I、II的结构，或其药用可接受的盐、酯或前药：这些化合物抑制丝氨酸蛋白酶活性，特别是乙型肝炎病毒（HCV）NS3-NS4A蛋白酶的活性。因此，本发明的化合物干扰了乙型肝炎病毒的生命周期，并且还可用作抗病毒剂。更具体地，本发明涉及含有环戊二烯基P2单元的肟化合物。本发明还涉及包括上述化合物的药物组合物，用于给患有HCV感染的受试者。该发明还涉及通过给予含有本发明化合物的药物组合物来治疗受试者的HCV感染的方法。